Deltex Medical (LON:DEMG) has been given approval to sell its paediatric blood flow monitoring probes in the US by the Food and Drug Adminstration.
The probe is designed to be used alongside Deltex’s CardioQ-ODM+ monitors on children who weigh three or more kilograms and are under the age of sixteen.
Deltex has sold the probe in Europe for the ten years and has achieved traction in a number of leading children's hospitals.
In the US there are a higher proportion of specialist paediatric hospitals in comparison to Europe, with a dedicated hospital for children in most of the larger cities.
The paediatric probe monitors drug and fluid therapies in an intensive care environment.
Ewan Phillips, chief executive, said: "FDA approval for our paediatric monitoring systems and single patient probes is excellent news for paediatricians in the USA who have, to date, had no safe or easy system in place to understand and monitor sick children's' haemodynamics in a surgical setting."
Discussions are already underway with a number of major children's' hospitals wanting to trial the CardioQ-ODM+, he said with first revenues in the second half of the year.